Granules India Limited (IN:GRANULES)
:GRANULES
Want to see IN:GRANULES full AI Analyst Report?
GRANULES Stock Chart & Stats
₹615.10
₹1.80(0.30%)
At close: 4:00 PM EST
₹615.10
₹1.80(0.30%)
Day’s Range― - ―
52-Week Range₹433.00 - ₹804.05
Previous CloseN/A
Volume528.44K
Average Volume (3M)56.05K
Market Cap
₹189.11B
Enterprise Value₹197.39B
Total Cash (Recent Filing)₹6.26B
Total Debt (Recent Filing)₹18.07B
Price to Earnings (P/E)31.5
Beta0.82
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.24%
Share Statistics
EPS (TTM)21.14
Shares Outstanding247,796,920
10 Day Avg. Volume60,875
30 Day Avg. Volume56,048
Financial Highlights & Ratios
PEG Ratio1.39
Price to Book (P/B)2.97
Price to Sales (P/S)2.81
P/FCF Ratio125.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)32.2
Revenue Forecast (FY)₹62.39B
Bulls Say, Bears Say
Bulls Say
Vertical Integration & Diversified RevenueGranules’ integrated model across APIs, PFIs and FDFs creates durable operational advantages: it reduces supplier exposure, captures margin across the value chain, and leverages scale for cost efficiency. These structural traits support stable revenues and long-term margin resilience.
Conservative Leverage And Balance-sheet StrengthManageable debt metrics give the company financial flexibility to invest in capacity, absorb cyclical shocks, and pursue opportunities without forcing distressed financing. A stable balance sheet supports capital allocation for growth and protects credit access over the medium term.
Revenue Recovery With Solid ProfitabilityResumed top-line growth alongside maintained profitability indicates demand resilience for core generics and manufacturing services. Consistent earnings provide a foundation for reinvestment, debt servicing and multi-year planning, supporting sustained business operations.
Bears Say
Margin Compression / Cost PressureA drop in gross profit while revenue grew signals structural margin headwinds—rising input costs, pricing erosion, or mix shifts. If persistent, this reduces operating leverage, squeezes operating cash flow, and constrains the company’s ability to restore historical profitability levels.
Uneven Free Cash Flow / Weak Cash ConversionVolatile free cash flow and weaker cash conversion versus earnings reflect working-capital and capex absorption. This pattern limits internal funding for growth, reduces financial cushions in downturns, and can force reliance on external financing for expansion or shareholder returns.
Declining Return On EquityA sustained fall in ROE indicates lower capital efficiency and weaker incremental returns on invested capital. Over time this can pressure shareholder value and signal that recent investments or pricing/mix shifts are yielding lower profitability per rupee deployed.
Granules India Limited News
GRANULES FAQ
What was Granules India Limited’s price range in the past 12 months?
Granules India Limited lowest stock price was ₹433.00 and its highest was ₹804.05 in the past 12 months.
What is Granules India Limited’s market cap?
Granules India Limited’s market cap is ₹189.11B.
When is Granules India Limited’s upcoming earnings report date?
Granules India Limited’s upcoming earnings report date is Aug 12, 2026 which is in 60 days.
How were Granules India Limited’s earnings last quarter?
Granules India Limited released its earnings results on Apr 29, 2026. The company reported ₹7.6 earnings per share for the quarter, beating the consensus estimate of ₹6.05 by ₹1.55.
Is Granules India Limited overvalued?
According to Wall Street analysts Granules India Limited’s price is currently Overvalued.
Does Granules India Limited pay dividends?
Granules India Limited pays a Annually dividend of ₹1.75 which represents an annual dividend yield of 0.24%. See more information on Granules India Limited dividends here
What is Granules India Limited’s EPS estimate?
Granules India Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Granules India Limited have?
Granules India Limited has 247,796,920 shares outstanding.
What happened to Granules India Limited’s price movement after its last earnings report?
Granules India Limited reported an EPS of ₹7.6 in its last earnings report, beating expectations of ₹6.05. Following the earnings report the stock price went up 0.078%.
Which hedge fund is a major shareholder of Granules India Limited?
Currently, no hedge funds are holding shares in IN:GRANULES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Granules India Limited
Founded in 1984 and headquartered in Hyderabad, India, Granules India Limited operates as a key player in the pharmaceutical sector. The company is engaged in the manufacturing and global distribution of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs), intermediate compounds for drug formulation, and final dosage forms (FDFs). Its API portfolio addresses various therapeutic categories, such as antiviral medications, treatments for hypertension, antihistamines, anti-infectives, pain relief agents, anticoagulants, anti-fibrinolytic drugs, and platelet inhibitors. Additionally, Granules produces a variety of FDFs, encompassing tablets, caplets, and press-fit capsules, which are supplied in bulk, blister packs, and bottles. The firm also develops specialized products for oncology. Granules India Limited maintains a broad international presence, with its products reaching markets across India, North America, Europe, Latin America, Africa, and the Middle East.
Technical Analysis
Alembic Pharmaceuticals Limited
―
Aurobindo Pharma Ltd
―
Cipla Ltd
―
Glenmark Pharmaceuticals Limited
―
Sanofi India Limited
―